irinotecan has been researched along with Osteosarcoma in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ding, K; Kang, S; McEachern, D; Miller, R; Nikolovska-Coleska, Z; Qin, D; Qiu, S; Shangary, S; Wang, G; Wang, S; Yang, D; Yu, S | 1 |
| Carrabotta, M; Cristalli, C; Donati, DM; Ferracin, M; Giusti, V; Ianzano, ML; Landuzzi, L; Lollini, PL; Magnani, M; Manara, MC; Nanni, P; Nicoletti, G; Palladini, A; Parra, A; Pasello, M; Picci, P; Righi, A; Ruzzi, F; Scotlandi, K | 1 |
| Li, Y; Qu, J; Zhang, P; Zhang, Z | 1 |
| Balaguer-Lluna, L; Baulenas-Farres, M; Burgueño, V; Carcaboso, AM; Carrasco, R; Castañeda, A; Castillo-Ecija, H; Celis, V; Cruz, O; Cuadrado-Vilanova, M; Garraus, M; Gorostegui, M; Jimenez-Cabaco, A; Krauel, L; Lavarino, C; Manzanares, A; Monterrubio, C; Mora, J; Morales La Madrid, A; Muñoz-Aznar, O; Olaciregui, NG; Pascual-Pasto, G; Perez-Jaume, S; Resa-Pares, C; Salvador, N; Santa-Maria, V; Suñol, M; Torner, F; Vancells, M; Vicario, FJ; Vila-Ubach, M | 1 |
| Ju, HY; Kang, HG; Kim, JH; Lee, JA; Park, BK; Park, HJ; Park, M; Park, SY; Yang, HC | 1 |
| Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Abril, J; Asad, O; Daniel, D; Dickman, P; Faraj, J; Foote, J; Hingorani, P; Kumar, S; Sertil, AR; Sharath, V; White-Collins, A; Yarapureddy, S | 1 |
| Berland, E; Filipski, E; Guettier, C; Lévi, F; Okyar, A; Ozturk, N; van der Horst, GT | 1 |
| Mukai, S; Naito, Y; Nojima, H; Ohno, S; Yabuta, N | 1 |
| Adachi, S; Hiraumi, Y; Itoh, K; Matsubara, H; Naka, N; Nakahata, T; Sano, K; Watanabe, K; Watanabe, M; Yoshioka, K; Yui, Y | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Boven, E; Bras, J; Gerritsen, WR; Haisma, HJ; Kruyt, FA; Molenaar, B; Oosterhoff, D; Pinedo, HM; Schaap, GR; van Beusechem, VW; Witlox, MA; Wuisman, PI | 1 |
| Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
| Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF | 1 |
| Crews, KR; Daw, NC; Liu, T; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Crassard, N; Frappaz, D; Marec-Bérard, P; Philip, T; Ranchin, B; Schell, M; Thiesse, P | 1 |
| Bissery, MC; D'Attino, RM; Filipski, E; Garufi, C; Granda, TG; Lévi, F; Terzoli, E; Vrignaud, P | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
2 review(s) available for irinotecan and Osteosarcoma
| Article | Year |
|---|---|
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
1 trial(s) available for irinotecan and Osteosarcoma
| Article | Year |
|---|---|
Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Drug Interactions; Female; Humans; Ifosfamide; Irinotecan; Male; Osteosarcoma; Pharmacokinetics | 2004 |
17 other study(ies) available for irinotecan and Osteosarcoma
| Article | Year |
|---|---|
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Bone Neoplasms; Cell Line, Tumor; Drug Design; HCT116 Cells; Humans; Indoles; Mice; Morpholines; Osteosarcoma; Piperazines; Proto-Oncogene Proteins c-mdm2; Rats; Spiro Compounds; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2009 |
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Topics: 12E7 Antigen; Animals; Antibodies; Antineoplastic Agents; Bone Neoplasms; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Osteosarcoma; Sarcoma, Ewing; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2019 |
Reduction-responsive sulfur dioxide polymer prodrug nanoparticles loaded with irinotecan for combination osteosarcoma therapy.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Female; Humans; Irinotecan; Mice, Inbred BALB C; Micelles; Nanoparticles; Osteosarcoma; Oxidation-Reduction; Polymers; Prodrugs; Sulfur Dioxide; Topoisomerase I Inhibitors | 2020 |
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Topics: Adolescent; Animals; Child; Child, Preschool; Disease Models, Animal; Female; Heterografts; Humans; Irinotecan; Male; Mice; Osteosarcoma; Prognosis; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Vincristine; Young Adult | 2022 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neuroblastoma; Osteosarcoma; Remission Induction; Retreatment; Rhabdomyosarcoma; Sarcoma, Ewing; Survival Rate; Temozolomide; Vincristine; Wilms Tumor | 2019 |
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Topics: Adolescent; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Irinotecan; Male; Mice, Nude; Osteosarcoma; Topoisomerase I Inhibitors; Trabectedin | 2019 |
ATF6α Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma.
Topics: Activating Transcription Factor 6; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Membrane Glycoproteins; Osteosarcoma; Oxidoreductases Acting on Sulfur Group Donors; Prognosis; Protein Disulfide-Isomerases; RNA, Small Interfering | 2019 |
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Camptothecin; Cell Line, Tumor; Chronotherapy; Circadian Rhythm; Cyclosporins; Endpoint Determination; Female; Ileum; Irinotecan; Mice; Mucous Membrane; Osteosarcoma; RNA, Messenger; Time Factors | 2014 |
ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Camptothecin; Cell Line, Tumor; Chemoradiotherapy; Cyclin G1; Doxycycline; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Osteosarcoma; Peptides; Phosphorylation; Protein Binding; Protein Phosphatase 2; Tumor Suppressor Protein p53 | 2015 |
Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8.
Topics: Animals; Camptothecin; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Irinotecan; Lung Neoplasms; Mesoderm; Mice; Mice, Inbred C3H; Osteosarcoma; Signal Transduction | 2010 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Mice, Nude; Osteosarcoma; Prodrugs; Transduction, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Quinazolines; Xenograft Model Antitumor Assays | 2004 |
Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Bone Neoplasms; Calcinosis; Camptothecin; Child; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Hematuria; Hemorrhage; Humans; Iatrogenic Disease; Ilium; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Methotrexate; Osteosarcoma; Radiography; Tibia; Ultrasonography, Interventional | 2008 |
Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Camptothecin; Drug Administration Schedule; Irinotecan; Male; Mice; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin | 2002 |